Date | Price Target | Rating | Analyst |
---|---|---|---|
10/1/2024 | $30.00 | Buy | H.C. Wainwright |
7/22/2024 | $23.00 | Buy | Needham |
7/8/2024 | $20.00 | Outperform | Mizuho |
12/12/2023 | $13.00 | Hold | Deutsche Bank |
10/10/2023 | $18.00 | Buy | BofA Securities |
10/10/2023 | $26.00 | Outperform | William Blair |
10/10/2023 | $21.00 | Overweight | JP Morgan |
10/10/2023 | $26.00 | Buy | Stifel |
4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
H.C. Wainwright initiated coverage of Neumora Therapeutics with a rating of Buy and set a new price target of $30.00
Needham initiated coverage of Neumora Therapeutics with a rating of Buy and set a new price target of $23.00
Mizuho initiated coverage of Neumora Therapeutics with a rating of Outperform and set a new price target of $20.00
WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will host a roundtable discussion on the neuropsychiatric treatment landscape and role of kappa opioid receptor antagonists (KORAs) in neuropsychiatry. The discussion will feature leading experts in neuropsychiatry and will take place on Thursday, September 12 at 8:00 a.m. ET. "We look forward to an engaging discussion with our panel of distinguished medical experts and to providing an overview of the potential for navacapra
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected in fourth quarter of 2024 Progressing clinical studies in MDD, bipolar depression and Alzheimer's disease agitation, providing opportunity for multiple value-creating catalysts over next 18 months Strong financial position with $371.6 million in cash, cash equivalents and marketable securities expected to support operations into 2026 WATERTOWN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced financial results for the second quarter e
NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and anxiety response NMRA-511 was generally well-tolerated at all dose levels in Phase 1 single ascending dose / multiple ascending dose study, with no serious adverse events reported to date Alzheimer's disease agitation is associated with increased morbidity and mortality and creates significant burden for patients and caregivers WATERTOWN, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical an
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024 Strong financial position with $463.8 million in cash, cash equivalents and marketable securities expected to support operations into 2026 WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update. "2023 was a watershed year for Neumora as we
WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora's executive team, reporting to Henry Gosebruch, president and chief executive officer. Ms. Pai Panandiker has more than 20 years of experience commercializing medicines in areas of significant unmet need, including the commercial launches of TRINTELLIX® (vortioxetine) and REXULTI® (brexpiprazole) for major depressive disorder (MDD) and schizophrenia. "I am excited to welcome Kaya to Neumora. As we progress t
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Jason Duncan as chief legal officer. Mr. Duncan will be a member of Neumora's Executive Team, reporting to Henry Gosebruch, chief executive officer, and will oversee all aspects of the Company's legal and compliance functions. "I am pleased to welcome Jason to Neumora. With his unique background that combines legal expertise with program strategy, I am confident that he will be a valuable addition to our team as we seek to deliver on our mission to redefine neuroscience drug dev
Needham analyst Ami Fadia initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Buy rating and announces Price Target of $23.
Mizuho analyst Graig Suvannavejh initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Outperform rating and announces Price Target of $20.
S-3ASR - Neumora Therapeutics, Inc. (0001885522) (Filer)
10-Q - Neumora Therapeutics, Inc. (0001885522) (Filer)
8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)